| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 112 | 2025 | 2535 | 10.710 |
Why?
|
| HIV-1 | 49 | 2025 | 747 | 7.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 35 | 2025 | 276 | 5.140 |
Why?
|
| Galectins | 14 | 2026 | 29 | 4.810 |
Why?
|
| CD8-Positive T-Lymphocytes | 26 | 2024 | 181 | 4.090 |
Why?
|
| Monocytes | 25 | 2025 | 275 | 3.330 |
Why?
|
| Anti-Retroviral Agents | 19 | 2025 | 158 | 2.550 |
Why?
|
| Simian immunodeficiency virus | 9 | 2026 | 61 | 2.520 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 9 | 2026 | 57 | 2.410 |
Why?
|
| Anti-HIV Agents | 20 | 2025 | 475 | 2.360 |
Why?
|
| DNA Methylation | 10 | 2025 | 393 | 2.240 |
Why?
|
| Viral Load | 24 | 2026 | 344 | 2.180 |
Why?
|
| Humans | 165 | 2026 | 42163 | 2.080 |
Why?
|
| Membrane Proteins | 10 | 2020 | 548 | 1.980 |
Why?
|
| Metformin | 3 | 2023 | 74 | 1.980 |
Why?
|
| Epigenesis, Genetic | 8 | 2025 | 274 | 1.930 |
Why?
|
| AIDS Dementia Complex | 6 | 2024 | 116 | 1.920 |
Why?
|
| Virus Latency | 11 | 2025 | 49 | 1.640 |
Why?
|
| Inflammation | 19 | 2025 | 729 | 1.600 |
Why?
|
| RNA, Viral | 11 | 2020 | 317 | 1.560 |
Why?
|
| T-Lymphocytes | 14 | 2024 | 378 | 1.500 |
Why?
|
| Antigens, CD | 9 | 2024 | 122 | 1.450 |
Why?
|
| Brain | 13 | 2025 | 1452 | 1.440 |
Why?
|
| Killer Cells, Natural | 11 | 2024 | 99 | 1.420 |
Why?
|
| Middle Aged | 60 | 2025 | 11819 | 1.370 |
Why?
|
| Aging | 11 | 2025 | 764 | 1.330 |
Why?
|
| Male | 80 | 2026 | 22779 | 1.280 |
Why?
|
| Dendritic Cells | 6 | 2025 | 130 | 1.250 |
Why?
|
| Receptors, Immunologic | 6 | 2024 | 70 | 1.250 |
Why?
|
| Myeloid Cells | 2 | 2019 | 31 | 1.230 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2024 | 91 | 1.220 |
Why?
|
| Intestinal Mucosa | 3 | 2026 | 131 | 1.210 |
Why?
|
| Immunotherapy | 3 | 2016 | 137 | 1.150 |
Why?
|
| Macaca mulatta | 11 | 2026 | 139 | 1.130 |
Why?
|
| Cognition | 9 | 2025 | 458 | 1.130 |
Why?
|
| CD4 Lymphocyte Count | 14 | 2025 | 200 | 1.110 |
Why?
|
| Female | 74 | 2025 | 24018 | 1.090 |
Why?
|
| Insulin Resistance | 5 | 2020 | 199 | 1.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 12 | 2023 | 229 | 1.040 |
Why?
|
| Cytokines | 16 | 2024 | 661 | 1.030 |
Why?
|
| Lymphocyte Activation | 17 | 2024 | 244 | 1.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2023 | 225 | 0.980 |
Why?
|
| Organoids | 3 | 2025 | 33 | 0.970 |
Why?
|
| Adult | 50 | 2025 | 13458 | 0.950 |
Why?
|
| HIV | 6 | 2023 | 100 | 0.940 |
Why?
|
| Human T-lymphotropic virus 1 | 5 | 2024 | 35 | 0.910 |
Why?
|
| Viremia | 4 | 2025 | 44 | 0.890 |
Why?
|
| Paraparesis, Tropical Spastic | 3 | 2024 | 13 | 0.890 |
Why?
|
| Central Nervous System | 5 | 2023 | 150 | 0.890 |
Why?
|
| Retroelements | 1 | 2024 | 14 | 0.890 |
Why?
|
| HTLV-I Infections | 6 | 2024 | 33 | 0.850 |
Why?
|
| Flow Cytometry | 16 | 2024 | 411 | 0.840 |
Why?
|
| Central Nervous System Diseases | 2 | 2023 | 32 | 0.820 |
Why?
|
| Receptors, Cell Surface | 4 | 2018 | 146 | 0.790 |
Why?
|
| Virus Replication | 5 | 2023 | 318 | 0.780 |
Why?
|
| Cardiovascular Diseases | 10 | 2023 | 729 | 0.780 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 3 | 2018 | 22 | 0.780 |
Why?
|
| Caspases | 2 | 2022 | 148 | 0.760 |
Why?
|
| Animals | 37 | 2026 | 16695 | 0.720 |
Why?
|
| Aged | 20 | 2025 | 7982 | 0.710 |
Why?
|
| Autoantibodies | 3 | 2025 | 112 | 0.700 |
Why?
|
| Vaccines | 1 | 2022 | 64 | 0.690 |
Why?
|
| T-Lymphocytes, Regulatory | 8 | 2015 | 68 | 0.680 |
Why?
|
| Communicable Diseases | 1 | 2021 | 47 | 0.680 |
Why?
|
| Leukocytes, Mononuclear | 8 | 2022 | 246 | 0.670 |
Why?
|
| Hepatitis C | 1 | 2022 | 138 | 0.660 |
Why?
|
| Lipoproteins, LDL | 1 | 2020 | 66 | 0.660 |
Why?
|
| Membrane Glycoproteins | 8 | 2016 | 221 | 0.650 |
Why?
|
| Genome, Human | 1 | 2021 | 143 | 0.650 |
Why?
|
| Blood Platelets | 1 | 2020 | 80 | 0.650 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 18 | 0.640 |
Why?
|
| Plasma | 6 | 2025 | 38 | 0.640 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2024 | 29 | 0.630 |
Why?
|
| Receptors, CCR5 | 6 | 2022 | 64 | 0.610 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 138 | 0.600 |
Why?
|
| Cognition Disorders | 2 | 2022 | 243 | 0.580 |
Why?
|
| Endogenous Retroviruses | 5 | 2023 | 17 | 0.560 |
Why?
|
| Cross-Sectional Studies | 21 | 2024 | 3077 | 0.560 |
Why?
|
| Atherosclerosis | 6 | 2023 | 164 | 0.560 |
Why?
|
| Drug Resistance, Viral | 1 | 2017 | 67 | 0.530 |
Why?
|
| Drug Therapy | 1 | 2016 | 17 | 0.500 |
Why?
|
| Neopterin | 3 | 2022 | 13 | 0.500 |
Why?
|
| Receptors, Tumor Necrosis Factor | 7 | 2008 | 38 | 0.500 |
Why?
|
| Cyclohexanes | 2 | 2023 | 30 | 0.490 |
Why?
|
| West Nile Fever | 2 | 2014 | 64 | 0.470 |
Why?
|
| Cohort Studies | 11 | 2025 | 1729 | 0.460 |
Why?
|
| Triazoles | 2 | 2023 | 100 | 0.460 |
Why?
|
| Case-Control Studies | 9 | 2023 | 1266 | 0.460 |
Why?
|
| Immunophenotyping | 10 | 2021 | 57 | 0.440 |
Why?
|
| Interleukin-1beta | 4 | 2025 | 74 | 0.430 |
Why?
|
| Apyrase | 2 | 2013 | 3 | 0.430 |
Why?
|
| West Nile virus | 2 | 2014 | 74 | 0.410 |
Why?
|
| Neuropsychological Tests | 6 | 2025 | 281 | 0.410 |
Why?
|
| Lymphocyte Subsets | 2 | 2018 | 21 | 0.410 |
Why?
|
| Immunoglobulin G | 3 | 2025 | 253 | 0.400 |
Why?
|
| Natural Killer T-Cells | 2 | 2010 | 11 | 0.400 |
Why?
|
| Receptors, CCR2 | 4 | 2018 | 28 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2020 | 379 | 0.390 |
Why?
|
| Signal Transduction | 11 | 2024 | 2111 | 0.390 |
Why?
|
| Mice | 18 | 2024 | 6490 | 0.390 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2024 | 72 | 0.390 |
Why?
|
| Lymphoid Tissue | 2 | 2025 | 19 | 0.390 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2024 | 106 | 0.390 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 1554 | 0.380 |
Why?
|
| Interleukin-17 | 3 | 2010 | 53 | 0.380 |
Why?
|
| Interleukin-2 | 3 | 2010 | 90 | 0.380 |
Why?
|
| Mutation | 1 | 2017 | 1169 | 0.380 |
Why?
|
| Gene Products, tax | 2 | 2011 | 4 | 0.370 |
Why?
|
| Disease Progression | 8 | 2022 | 661 | 0.350 |
Why?
|
| Autoantigens | 2 | 2022 | 85 | 0.340 |
Why?
|
| Forkhead Transcription Factors | 3 | 2009 | 75 | 0.340 |
Why?
|
| Gene Expression Profiling | 3 | 2025 | 683 | 0.330 |
Why?
|
| CD4-CD8 Ratio | 3 | 2020 | 30 | 0.330 |
Why?
|
| Albuminuria | 3 | 2016 | 78 | 0.330 |
Why?
|
| Retrospective Studies | 6 | 2023 | 2485 | 0.330 |
Why?
|
| Proviruses | 3 | 2025 | 35 | 0.320 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 2 | 2020 | 4 | 0.310 |
Why?
|
| Receptors, IgG | 5 | 2022 | 53 | 0.310 |
Why?
|
| Carotid Arteries | 3 | 2022 | 35 | 0.310 |
Why?
|
| Cells, Cultured | 9 | 2024 | 1617 | 0.310 |
Why?
|
| DNA, Viral | 3 | 2016 | 323 | 0.300 |
Why?
|
| Interleukin-6 | 3 | 2020 | 165 | 0.300 |
Why?
|
| DNA, Mitochondrial | 2 | 2023 | 185 | 0.290 |
Why?
|
| Lymphocyte Count | 6 | 2021 | 47 | 0.290 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 25 | 0.290 |
Why?
|
| Young Adult | 13 | 2025 | 4936 | 0.280 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 708 | 0.280 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2007 | 2 | 0.280 |
Why?
|
| Mice, Transgenic | 7 | 2022 | 658 | 0.280 |
Why?
|
| Macaca fascicularis | 2 | 2024 | 64 | 0.270 |
Why?
|
| Veterans | 2 | 2020 | 203 | 0.270 |
Why?
|
| Comorbidity | 4 | 2024 | 725 | 0.270 |
Why?
|
| Immunity, Mucosal | 2 | 2024 | 52 | 0.270 |
Why?
|
| Meninges | 2 | 2018 | 6 | 0.270 |
Why?
|
| Coronary Vessels | 2 | 2019 | 92 | 0.260 |
Why?
|
| Chemokine CCL2 | 3 | 2025 | 95 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 577 | 0.260 |
Why?
|
| Longitudinal Studies | 8 | 2024 | 1020 | 0.250 |
Why?
|
| Treatment Outcome | 3 | 2025 | 1586 | 0.250 |
Why?
|
| India | 2 | 2024 | 105 | 0.250 |
Why?
|
| Auranofin | 1 | 2025 | 3 | 0.240 |
Why?
|
| Niacinamide | 1 | 2025 | 16 | 0.240 |
Why?
|
| Tuberculosis | 2 | 2024 | 76 | 0.240 |
Why?
|
| Adolescent | 5 | 2024 | 5950 | 0.240 |
Why?
|
| Disease Reservoirs | 1 | 2025 | 24 | 0.240 |
Why?
|
| Combined Modality Therapy | 1 | 2025 | 174 | 0.230 |
Why?
|
| Host-Pathogen Interactions | 5 | 2021 | 203 | 0.230 |
Why?
|
| Schistosomiasis haematobia | 1 | 2024 | 3 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2024 | 17 | 0.220 |
Why?
|
| Schistosoma haematobium | 1 | 2024 | 2 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 53 | 0.220 |
Why?
|
| Gene Expression | 3 | 2024 | 692 | 0.220 |
Why?
|
| HLA-DR Antigens | 2 | 2022 | 23 | 0.220 |
Why?
|
| Flavonols | 1 | 2024 | 15 | 0.210 |
Why?
|
| Immunoglobulin A | 1 | 2024 | 63 | 0.210 |
Why?
|
| Lentivirus Infections | 1 | 2023 | 1 | 0.210 |
Why?
|
| Influenza, Human | 2 | 2024 | 90 | 0.210 |
Why?
|
| Immunoassay | 1 | 2024 | 69 | 0.210 |
Why?
|
| Herpesviridae Infections | 1 | 2023 | 18 | 0.210 |
Why?
|
| Adipose Tissue | 2 | 2016 | 180 | 0.210 |
Why?
|
| Macrophages | 3 | 2018 | 515 | 0.210 |
Why?
|
| Quercetin | 1 | 2024 | 46 | 0.210 |
Why?
|
| Sarcoma, Kaposi | 1 | 2023 | 24 | 0.210 |
Why?
|
| Virus Activation | 3 | 2021 | 38 | 0.210 |
Why?
|
| Staphylococcus aureus | 1 | 2024 | 91 | 0.210 |
Why?
|
| Pilot Projects | 3 | 2024 | 733 | 0.200 |
Why?
|
| Herpesvirus 8, Human | 1 | 2023 | 29 | 0.200 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2024 | 31 | 0.200 |
Why?
|
| Macaca | 1 | 2023 | 36 | 0.200 |
Why?
|
| Child | 4 | 2024 | 3381 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2014 | 1420 | 0.200 |
Why?
|
| RNA | 2 | 2022 | 266 | 0.200 |
Why?
|
| Risk Factors | 10 | 2023 | 3942 | 0.200 |
Why?
|
| Integrins | 2 | 2018 | 54 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2025 | 253 | 0.200 |
Why?
|
| Biomedical Research | 2 | 2019 | 467 | 0.200 |
Why?
|
| Phenotype | 9 | 2024 | 774 | 0.200 |
Why?
|
| Exosomes | 1 | 2024 | 124 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 13 | 0.190 |
Why?
|
| Interleukin-8 | 2 | 2020 | 74 | 0.190 |
Why?
|
| Dengue | 2 | 2014 | 100 | 0.190 |
Why?
|
| Imidazoles | 2 | 2024 | 138 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 11 | 2024 | 1804 | 0.190 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 15 | 0.190 |
Why?
|
| Leukocyte Count | 3 | 2019 | 68 | 0.190 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 96 | 0.190 |
Why?
|
| Cerebrospinal Fluid | 1 | 2022 | 20 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 6 | 2024 | 301 | 0.190 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 196 | 0.180 |
Why?
|
| Cyclopropanes | 1 | 2022 | 42 | 0.180 |
Why?
|
| Immunity, Innate | 3 | 2019 | 168 | 0.180 |
Why?
|
| Calcium | 2 | 2016 | 487 | 0.180 |
Why?
|
| Alkynes | 1 | 2022 | 50 | 0.180 |
Why?
|
| Vietnam | 1 | 2022 | 61 | 0.180 |
Why?
|
| Benzoxazines | 1 | 2022 | 46 | 0.180 |
Why?
|
| Heart Diseases | 1 | 2023 | 110 | 0.180 |
Why?
|
| Flavivirus | 1 | 2022 | 16 | 0.180 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 245 | 0.180 |
Why?
|
| Interferon-gamma | 8 | 2015 | 268 | 0.180 |
Why?
|
| Interleukin-10 | 2 | 2014 | 86 | 0.180 |
Why?
|
| Hepacivirus | 1 | 2022 | 73 | 0.180 |
Why?
|
| Atrophy | 2 | 2024 | 51 | 0.180 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2001 | 55 | 0.170 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 188 | 0.170 |
Why?
|
| Fusobacteria | 1 | 2020 | 4 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 249 | 0.170 |
Why?
|
| Bone Diseases | 1 | 2020 | 18 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 16 | 0.170 |
Why?
|
| Cystatin C | 1 | 2020 | 25 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 35 | 0.170 |
Why?
|
| Fasting | 1 | 2020 | 56 | 0.170 |
Why?
|
| Immunologic Memory | 3 | 2021 | 41 | 0.170 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 48 | 0.170 |
Why?
|
| Blood Glucose | 2 | 2020 | 386 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2020 | 101 | 0.160 |
Why?
|
| Corpus Callosum | 1 | 2020 | 14 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 358 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 56 | 0.160 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 58 | 0.160 |
Why?
|
| Thailand | 2 | 2020 | 51 | 0.160 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 68 | 0.160 |
Why?
|
| Philippines | 2 | 2017 | 80 | 0.160 |
Why?
|
| Research | 1 | 2021 | 177 | 0.160 |
Why?
|
| Echocardiography | 1 | 2020 | 167 | 0.160 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 190 | 0.160 |
Why?
|
| Angiopoietins | 1 | 2019 | 2 | 0.150 |
Why?
|
| Heart | 1 | 2020 | 181 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 81 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 86 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2019 | 146 | 0.150 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 14 | 0.150 |
Why?
|
| Disease Management | 2 | 2021 | 68 | 0.150 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2023 | 17 | 0.150 |
Why?
|
| Ligands | 4 | 2012 | 387 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2019 | 81 | 0.150 |
Why?
|
| E-Selectin | 1 | 2018 | 23 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 66 | 0.150 |
Why?
|
| Cell Line | 4 | 2019 | 1416 | 0.150 |
Why?
|
| Genes, MHC Class I | 1 | 2018 | 14 | 0.150 |
Why?
|
| Prevalence | 1 | 2023 | 1597 | 0.140 |
Why?
|
| Transcription, Genetic | 4 | 2024 | 599 | 0.140 |
Why?
|
| Cell Differentiation | 3 | 2012 | 633 | 0.140 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 67 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.140 |
Why?
|
| Cameroon | 3 | 2023 | 35 | 0.140 |
Why?
|
| Cell Separation | 2 | 2016 | 94 | 0.140 |
Why?
|
| Age Factors | 2 | 2018 | 1139 | 0.140 |
Why?
|
| Neural Pathways | 1 | 2018 | 139 | 0.140 |
Why?
|
| Th1 Cells | 2 | 2024 | 97 | 0.140 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2017 | 35 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2018 | 124 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 23 | 0.130 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2017 | 56 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 189 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 532 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 1066 | 0.130 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 160 | 0.130 |
Why?
|
| Brain Injuries | 1 | 2018 | 133 | 0.130 |
Why?
|
| Coronary Artery Disease | 2 | 2019 | 164 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2022 | 501 | 0.120 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 26 | 0.120 |
Why?
|
| Mitochondria | 1 | 2020 | 516 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 103 | 0.120 |
Why?
|
| Lymphatic System | 1 | 2015 | 4 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 100 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 37 | 0.120 |
Why?
|
| Bilirubin | 1 | 2016 | 19 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2025 | 1574 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2024 | 534 | 0.120 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 21 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 233 | 0.120 |
Why?
|
| Brachial Artery | 1 | 2015 | 27 | 0.120 |
Why?
|
| Microglia | 3 | 2025 | 204 | 0.120 |
Why?
|
| Mice, Knockout | 6 | 2018 | 1010 | 0.120 |
Why?
|
| Vasodilation | 1 | 2015 | 64 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 97 | 0.120 |
Why?
|
| Receptors, Chemokine | 2 | 2013 | 72 | 0.120 |
Why?
|
| ADAM Proteins | 1 | 2015 | 20 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2015 | 35 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 34 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 26 | 0.110 |
Why?
|
| Lung | 1 | 2018 | 484 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2018 | 324 | 0.110 |
Why?
|
| Lipoproteins | 1 | 2014 | 68 | 0.110 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2013 | 18 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 196 | 0.110 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2014 | 12 | 0.110 |
Why?
|
| Thrombin | 1 | 2014 | 28 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2014 | 29 | 0.110 |
Why?
|
| Ionomycin | 1 | 2014 | 11 | 0.110 |
Why?
|
| OX40 Ligand | 6 | 2004 | 6 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2014 | 67 | 0.110 |
Why?
|
| Tumor Necrosis Factors | 6 | 2004 | 13 | 0.110 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2014 | 42 | 0.110 |
Why?
|
| Osteopontin | 1 | 2014 | 45 | 0.110 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2013 | 7 | 0.110 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2014 | 31 | 0.100 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2013 | 36 | 0.100 |
Why?
|
| Neuropilin-1 | 2 | 2022 | 4 | 0.100 |
Why?
|
| Hawaii | 5 | 2020 | 2004 | 0.100 |
Why?
|
| Dengue Virus | 1 | 2014 | 89 | 0.100 |
Why?
|
| Psoriasis | 1 | 2013 | 19 | 0.100 |
Why?
|
| Mucous Membrane | 2 | 2024 | 34 | 0.100 |
Why?
|
| Alternative Splicing | 2 | 2024 | 92 | 0.100 |
Why?
|
| Phosphoproteins | 2 | 2013 | 201 | 0.100 |
Why?
|
| Hippocampus | 1 | 2016 | 591 | 0.090 |
Why?
|
| Synapses | 1 | 2013 | 184 | 0.090 |
Why?
|
| Cross-Linking Reagents | 1 | 2012 | 51 | 0.090 |
Why?
|
| HIV Antibodies | 2 | 2022 | 24 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1188 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2017 | 541 | 0.090 |
Why?
|
| Skin | 1 | 2013 | 185 | 0.090 |
Why?
|
| RNA Splicing | 2 | 2024 | 42 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1559 | 0.090 |
Why?
|
| Depression | 1 | 2018 | 837 | 0.090 |
Why?
|
| Chemokine CCL3 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Chemokine CCL4 | 1 | 2010 | 19 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 136 | 0.090 |
Why?
|
| Proteomics | 2 | 2025 | 363 | 0.080 |
Why?
|
| Th2 Cells | 3 | 2010 | 63 | 0.080 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 4 | 0.080 |
Why?
|
| Receptors, OX40 | 4 | 2004 | 7 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2023 | 452 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2010 | 13 | 0.080 |
Why?
|
| Viral Matrix Proteins | 1 | 2010 | 18 | 0.080 |
Why?
|
| Cell Count | 1 | 2010 | 140 | 0.080 |
Why?
|
| Antigens, CD7 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Placenta | 2 | 2022 | 113 | 0.080 |
Why?
|
| Cell Division | 2 | 2007 | 314 | 0.080 |
Why?
|
| Carrier State | 1 | 2009 | 33 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 73 | 0.080 |
Why?
|
| Chemokines | 2 | 2023 | 97 | 0.080 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2009 | 30 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2016 | 456 | 0.080 |
Why?
|
| Fibrosis | 2 | 2022 | 166 | 0.070 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 143 | 0.070 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Interleukin-18 | 2 | 2023 | 16 | 0.070 |
Why?
|
| Receptors, KIR3DS1 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 2598 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2008 | 92 | 0.070 |
Why?
|
| Antigens, Viral | 1 | 2007 | 50 | 0.070 |
Why?
|
| Time Factors | 3 | 2020 | 1848 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 84 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 6 | 0.060 |
Why?
|
| Sex Factors | 2 | 2025 | 1008 | 0.060 |
Why?
|
| Africa South of the Sahara | 1 | 2025 | 51 | 0.060 |
Why?
|
| Chemokine CXCL10 | 1 | 2025 | 38 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 850 | 0.060 |
Why?
|
| Antigens | 2 | 2003 | 58 | 0.060 |
Why?
|
| Adoptive Transfer | 2 | 2002 | 50 | 0.060 |
Why?
|
| Pregnancy | 2 | 2022 | 1737 | 0.060 |
Why?
|
| San Francisco | 2 | 2019 | 34 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 37 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2025 | 105 | 0.060 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2024 | 5 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 845 | 0.060 |
Why?
|
| Bacillus anthracis | 1 | 2024 | 33 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2024 | 7 | 0.050 |
Why?
|
| Anthelmintics | 1 | 2024 | 21 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2024 | 45 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2024 | 50 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2004 | 9 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2004 | 21 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2004 | 39 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 23 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 686 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 246 | 0.050 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2023 | 13 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 22 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 34 | 0.050 |
Why?
|
| Cell Communication | 1 | 2004 | 110 | 0.050 |
Why?
|
| Colombia | 1 | 2023 | 30 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 2803 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 127 | 0.050 |
Why?
|
| Dermatitis, Contact | 1 | 2002 | 2 | 0.050 |
Why?
|
| Langerhans Cells | 1 | 2002 | 2 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2021 | 990 | 0.050 |
Why?
|
| Receptors, CCR7 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 180 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 64 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2025 | 355 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 131 | 0.050 |
Why?
|
| Individuality | 1 | 2022 | 53 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 115 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2022 | 30 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 162 | 0.050 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2001 | 9 | 0.050 |
Why?
|
| Exons | 1 | 2022 | 91 | 0.050 |
Why?
|
| Myelin Proteins | 1 | 2001 | 18 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2022 | 139 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2001 | 85 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2021 | 44 | 0.040 |
Why?
|
| Caspase 7 | 1 | 2021 | 18 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2021 | 16 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 163 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 114 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 508 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 183 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 71 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2020 | 13 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 557 | 0.040 |
Why?
|
| Astrocytes | 1 | 2022 | 244 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2021 | 226 | 0.040 |
Why?
|
| Cell Movement | 2 | 2015 | 640 | 0.040 |
Why?
|
| Research Personnel | 1 | 2022 | 191 | 0.040 |
Why?
|
| Anisotropy | 1 | 2020 | 33 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2023 | 426 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2000 | 31 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 27 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2014 | 973 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2019 | 18 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 283 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 167 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2019 | 4 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 49 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 73 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 65 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 107 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2022 | 960 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 84 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 242 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2018 | 17 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 95 | 0.040 |
Why?
|
| Geriatrics | 1 | 2019 | 67 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 189 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2023 | 1516 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 184 | 0.040 |
Why?
|
| Rest | 1 | 2018 | 33 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 62 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 438 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 115 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 59 | 0.040 |
Why?
|
| Eosinophils | 1 | 2018 | 22 | 0.040 |
Why?
|
| Malaria | 1 | 2019 | 90 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 122 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 54 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2018 | 20 | 0.040 |
Why?
|
| Epitopes | 1 | 2018 | 155 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 483 | 0.030 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 18 | 0.030 |
Why?
|
| Stroke | 1 | 2021 | 348 | 0.030 |
Why?
|
| Aorta | 1 | 2018 | 197 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 45 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 279 | 0.030 |
Why?
|
| Antigen Presentation | 2 | 2009 | 59 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1001 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 74 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2015 | 36 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 61 | 0.030 |
Why?
|
| Neurons | 1 | 2022 | 1246 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 19 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 28 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 75 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 454 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 65 | 0.030 |
Why?
|
| Immunization | 1 | 2015 | 93 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 860 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2014 | 4 | 0.030 |
Why?
|
| Thrombomodulin | 1 | 2014 | 5 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 165 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 44 | 0.030 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2013 | 7 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 167 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 884 | 0.030 |
Why?
|
| Phosphotransferases | 1 | 2014 | 35 | 0.030 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 8 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2018 | 1265 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 261 | 0.030 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 16 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 32 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 31 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 358 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 300 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 156 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 518 | 0.020 |
Why?
|
| Mesothelioma | 1 | 2015 | 148 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 279 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 289 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2013 | 50 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2013 | 106 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 462 | 0.020 |
Why?
|
| Hypertension | 1 | 2019 | 823 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 2011 | 11 | 0.020 |
Why?
|
| Gene Products, env | 1 | 2011 | 23 | 0.020 |
Why?
|
| Neoplasms | 1 | 2021 | 1341 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 662 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 2009 | 8 | 0.020 |
Why?
|
| Receptors, KIR | 1 | 2009 | 5 | 0.020 |
Why?
|
| K562 Cells | 1 | 2009 | 32 | 0.020 |
Why?
|
| Blood Donors | 1 | 2009 | 20 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2009 | 46 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 34 | 0.020 |
Why?
|
| Immunomagnetic Separation | 1 | 2009 | 4 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 113 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2008 | 4 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2008 | 7 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2008 | 27 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2008 | 6 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2008 | 48 | 0.020 |
Why?
|
| Galactosylceramides | 1 | 2008 | 12 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 105 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2008 | 3 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2008 | 11 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 98 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 160 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 649 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 26 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 796 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2004 | 5 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 32 | 0.010 |
Why?
|
| Leishmania major | 1 | 2003 | 23 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2002 | 3 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2002 | 6 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2002 | 5 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2002 | 48 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 72 | 0.010 |
Why?
|
| Homeostasis | 1 | 2004 | 193 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 141 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2002 | 59 | 0.010 |
Why?
|
| Isoantigens | 1 | 2000 | 5 | 0.010 |
Why?
|
| Culture Media | 1 | 2000 | 96 | 0.010 |
Why?
|